Eye Blood Flow Study in Diabetes Patients Starting New Medication
Part of Hormones & metabolism clinical trials.
This study measures blood flow in the eyes and how the retina (back of the eye) uses oxygen in people with diabetes who are starting a new type of diabetes medication. Researchers want to understand how these newer medications affect blood vessels in the eyes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diabetes mellitus
- You are 18 years or older
- You are planning to start a new diabetes medication (semaglutide, liraglutide, or tirzepatide) prescribed by your diabetes doctor
- Your eyes are generally healthy except for possible diabetic retinopathy (diabetes-related eye changes)
- You have not participated in another clinical trial in the past 3 weeks
- You have not had laser eye surgery in the study eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures blood flow and oxygen use in the retina (the light-sensing layer at the back of your eye) in adults with type 2 diabetes and in healthy adults. It may help researchers better understand how diabetes affects the eye.
This study checks whether a specific eye-scanning technology gives consistent, repeatable results. It enrolls healthy adults to see if the test works reliably before being used more broadly.
This study compares eye blood-flow/brain-eye communication signals in people with glaucoma (or high eye pressure) versus people with normal eye tests. It may help researchers understand how glaucoma develops and progresses.
This study uses a new, non-invasive laser imaging technique to measure blood flow in the eye. It aims to understand how blood flow is affected in certain eye and blood vessel conditions, which may help doctors manage treatments better.
This study compares two types of diabetes medications (GLP-1 receptor agonists and SGLT2 inhibitors) to see how they affect blood vessels in the back of the eye over time. It may help doctors understand if one drug is better for protecting your eyes.
This study uses a special camera (OCTA) to look at blood flow in the iris of people with or without type 2 diabetes and diabetic neovascular glaucoma. The goal is to understand how blood flow changes in this eye condition.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.